Primary Hypothesis High interindividual variability of Alemtuzumab PK in children transplanted for severe non-malignant diseases crucially impacts the cumulative exposure to Alemtuzumab given intravenously as part of a reduced intensity conditioning…
ID
Bron
Verkorte titel
Aandoening
Diagnosis of severe congenital immune deficiency or of congenital hematological disorder with indication for allogeneic stem cell transplantation
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Cumulative Alemtuzumab exposure (AUC) till day +7
Achtergrond van het onderzoek
In children, Alemtuzumab is increasingly administered off-label prior to allogeneic stem cell transplantation according to European guidelines. However, pediatric data on Alemtuzumab pharmacokinetics (PK) suggest large inter-patient variability, which significantly impacts biological efficacy and clinical outcome. Since optimal dosing of Alemtuzumab in children prior to HSCT is currently unknown, the need for further PK analyses allowing the evaluation of current clinical practice as well as possibly supporting improved patient care in this vulnerable participants group is urgent.
The aim of our observational study is to evaluate current clinical practice and develop a comprehensive population pharmacokinetic model for Alemtuzumab in children with non-malignant diseases treated with reduced intensity conditioning regimens prior to stem cell transplantation. This model will provide essential additional information on Alemtuzumab treatments and support the establishment of a rigorous therapeutic drug
monitoring.
Doel van het onderzoek
Primary Hypothesis
High interindividual variability of Alemtuzumab PK in children transplanted for severe non-malignant diseases crucially impacts the cumulative exposure to Alemtuzumab given intravenously as part of a reduced intensity conditioning regimen pre and post allogeneic stem cell transplantation.
Secondary Hypothesis
The exposure to Alemtuzumab correlates significantly with immune reconstitution, risk of acute and chronic GvHD and primary clinical outcome defined as incidence of infectious complications, reactive autoimmunity and secondary immune-endocrine disorders in children with non-malignant diseases undergoing alloHSCT.
Onderzoeksopzet
Alemtuzumab levels measured during Alemtuzumab administration as well weekly till 6 weeks after allogeneic stem cell transplantation.
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• diagnosis of severe congenital immune deficiency or of congenital hematological disorder with indication for allogeneic stem cell transplantation (HSCT)
• age at diagnosis and at the time of HSCT ≤ 18 years
• Alemtuzumab treatment intravenously is given as part of a treosulfan- or a busulfan-based reduced intensity conditioning regimen prior to HSCT
• all donor types and hematopoietic stem cell sources will be considered
• HSCT is performed in a study participating center
• written consent of the parents (legal guardian) and of the patient herself or himself if ≥14 years old (≥12 years old in the Netherlands)
• in case of multiple HSCT per patient, further transplantations will only be considered if a minimal serotherapy-free interval of 3 months is preceding the second transplant
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• patients who do not fulfill the inclusion criteria
• patients with known hypersensitivity to Alemtuzumab
• patients treated with other serotherapy drugs (e.g. anti-thymocyte globulin – ATG) within the same conditioning regimen prior to HSCT
• patients who received any other serotherapy in the last 3 months before starting this observational study
• known HIV-positivity
• active malignancy
• pregnancy/lactation
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8185 |
| CCMO | NL68506.058.19 |
| OMON | NL-OMON55607 |